We are live on ! Find out more
CC

Callan Capital Portfolio holdings

AUM $1.35B
1-Year Est. Return 8.35%
This Fund
S&P 500
This Quarter Est. Return
+6.26%
1 Year Est. Return
+8.35%
3 Year Est. Return
+20.11%
5 Year Est. Return
+98.58%
10 Year Est. Return
+95.87%
AUM
$864M
AUM Growth
+$54.1M
Cap. Flow
+$8.09M
Cap. Flow %
0.94%
Top 10 Hldgs %
50.84%
Holding
197
New
11
Increased
61
Reduced
63
Closed
13

Top Buys

Rank Stock Value
1
FNDX icon
Schwab Fundamental US Large Company Index ETF
FNDX
+$6.54M
2
SCHF icon
Schwab International Equity ETF
SCHF
+$2.93M
3
FNDF icon
Schwab Fundamental International Large Company Index ETF
FNDF
+$2.51M
4
SCHB icon
Schwab US Broad Market ETF
SCHB
+$1.79M
5
AVUV icon
Avantis US Small Cap Value ETF
AVUV
+$1.76M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$2.53M
2
JMST icon
JPMorgan Ultra-Short Municipal Income ETF
JMST
+$2.27M
3
VO icon
Vanguard Morningstar Mid-Cap ETF
VO
+$1.22M
4
USMV icon
iShares MSCI USA Min Vol Factor ETF
USMV
+$1.1M
5
GSLC icon
Goldman Sachs ActiveBeta US Large Cap Equity ETF
GSLC
+$803K

Sector Composition

Rank Sector Weight
1 Miscellaneous 90.85%
2 Technology 3.67%
3 Financials 1.29%
4 Healthcare 1.17%
5 Real Estate 0.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDTX
176
DELISTED
Cidara Therapeutics
CDTX
$131K 0.02%
5,173
– –
USBC
177
USBC Inc
USBC
$165M
$116K 0.01%
3,250
– –
ALLO icon
178
Allogene Therapeutics
ALLO
$698M
$95K 0.01%
19,224
– –
EQ icon
179
Equillium
EQ
$152M
$75.7K 0.01%
103,688
– –
INFI
180
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$25.4K ﹤0.01%
158,500
– –
CRDF icon
181
Cardiff Oncology
CRDF
$73.1M
$22.4K ﹤0.01%
13,587
– –
SRXH
182
SRX Global
SRXH
$34.7M
$16K ﹤0.01%
22
– –
EFTR
183
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$7.05K ﹤0.01%
800
– –
BINI
184
DELISTED
Bollinger Innovations
BINI
– –
0
– –
AES icon
185
AES
AES
$10.5B
– –
-11,216
Closed -$323K
DE icon
186
Deere & Co
DE
$170B
– –
-494
Closed -$212K
EFAV icon
187
iShares MSCI EAFE Min Vol Factor ETF
EFAV
$5.49B
– –
-5,039
Closed -$320K
FITB
188
Fifth Third Bancorp
FITB
$49.5B
– –
-6,103
Closed -$200K
HALO icon
189
Halozyme
HALO
$12B
– –
-4,770
Closed -$271K
HPQ icon
190
HP
HPQ
$27.5B
– –
-15,762
Closed -$424K
JAZZ icon
191
Jazz Pharmaceuticals
JAZZ
$15.9B
– –
-15,864
Closed -$2.53M
PNC icon
192
PNC Financial Services
PNC
$96.6B
– –
-3,243
Closed -$512K
RSP icon
193
Invesco S&P 500 Equal Weight ETF
RSP
$99.5B
– –
-1,630
Closed -$230K
T icon
194
AT&T
T
$178B
– –
-16,169
Closed -$298K
USMV icon
195
iShares MSCI USA Min Vol Factor ETF
USMV
$24.4B
– –
-15,260
Closed -$1.1M
V icon
196
Visa
V
$712B
– –
-1,292
Closed -$268K
VZ icon
197
Verizon
VZ
$208B
– –
-8,742
Closed -$344K
4 5 6 7
8

Similar funds

MBA
Maple-Brown Abbott Barangaroo, Australia $1.47B AUM 27.26% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
AP
Adero Partners Pleasanton, California $1.53B AUM 5.52% 1-Year Est. Return
MW
Marcum Wealth Cleveland, Ohio $1.16B AUM 6.7% 1-Year Est. Return
SBIA
Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return
TW
Transform Wealth Greenwood Village, Colorado $1.65B AUM 19.1% 1-Year Est. Return
PAME
Parvus Asset Management Europe London, United Kingdom $1.67B AUM

Callan Capital's Q1 2023 Portfolio in Review

As of Q1 2023, Callan Capital held 197 positions worth $864M, up 6.7% from $810M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Callan Capital's Q1 2023 filing shows 11 new, 61 increased, 63 reduced and 13 closed positions. Its largest new stake was Avantis US Small Cap Value ETF: 22,447 shares worth $1.66M. The largest sale was Jazz Pharmaceuticals, an estimated $2.53M.

By sector, the portfolio is most concentrated in Miscellaneous at 91% of assets, up from 90% a quarter earlier, followed by Technology and Financials.

  • Callan Capital's largest Q1 2023 buy was Avantis US Small Cap Value ETF: 22,447 shares worth $1.66M.
  • Callan Capital added most to Schwab Fundamental US Large Company Index ETF in Q1 2023, an estimated $6.54M increase.
  • Callan Capital's biggest Q1 2023 reduction was JPMorgan Ultra-Short Municipal Income ETF, cutting an estimated $2.27M.
  • Callan Capital fully exited Jazz Pharmaceuticals in Q1 2023, selling an estimated $2.53M.
  • Callan Capital's ten largest holdings make up 51% of its $864M portfolio in Q1 2023.
  • Callan Capital opened 11 new positions and closed 13 in Q1 2023.
  • Callan Capital's portfolio value rose 6.7% quarter-over-quarter to $864M.

Based on Callan Capital's 13F filing for Q1 2023, filed 9 May 2023.